Discitis of Thoracic RegionNCT07493473
Parascapular Sub Iliocostalis Plane Block Versus Thoracic Paravertebral Plane Block for Traumatic Multiple Rib Fractures
A study testing Thoracic paravertebral block and Parascapular Sub-Iliocostalis Plane Block in people with Discitis of Thoracic Region, run by Zagazig University at 1 site in Egypt.
Trial summary
Pain control of rib fractures is essential for not only primary pain relief but also preventing secondary complications such as atelectasis or pneumonia which increase the hospital stay, as well as the transition to chronic pain. Read more about this study
- Who is it for?
- Ages 21 to 60 years
- Conditions the study is for
- Discitis of Thoracic Region
- What is being tested?
- Thoracic paravertebral block and Parascapular Sub-Iliocostalis Plane Block
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 siteEgypt
- Study dates
- 1 May 2025to Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patient written informed consent.
- ASA I to III.
- Age 21-60 years old.
- Gender: Both.
- BMI < 35 Kg/M2.
- Accepted mental state of the patient.
- Patient with unilateral multiple rib fractures (≥2 fractures)
Who cannot join
- Any trauma in the patient that interfere with the positioning of patients for block.
- Patients who needed mechanical ventilation before or during the study.
- Patients with associated head trauma.
- Patient with hemodynamic instability and need inotropic support. • Patient with abbreviated injury scale (AIS) in extremity more than 2 (10)
- Pathological coagulopathy.
- Infection at the injection site.
Show all 9Show fewer
- Disturbed conscious level.
- An allergy to local anesthetics or any used drugs in this study.
- Pregnancy.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
D A Abo El Naga, MSC contact
Egypt1 site, 1 recruiting
- Recruiting
Zagazig university
Zagazig, Sharqia Province, 44111
R A Kamel, MD, +201229927122, ranion8598@gmail.com
D A Abo El Naga, MSc, +201022274433
About this study
Official title: Continuous Block of Parascapular Sub-Iliocostalis Plane Versus Thoracic Paravertebral Plane for Analgesia in Patients With Traumatic Multiple Rib Fractures
Pain control of rib fractures is essential for not only primary pain relief but also preventing secondary complications such as atelectasis or pneumonia which increase the hospital stay, as well as the transition to chronic pain.
The cornerstones of analgesic management are oral and intravenous medications such as paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids as well as regional block techniques as paravertebral block and thoracic epidural.
Read more
To avoid opioid as well as regional block related side effects such as pneumothorax and hemodynamic instability, previous studies showed that superficial chest wall block such as thoracic erector spinae plane block and serratus anterior plane block had shown a promising success in management of such pain with few side effects.
In an effort to reduce the pain score, hospital stay and improve the patient's capability of physiotherapy this study compares continuous block of parascapular sub-iliocostalis plane block versus continuous thoracic paravertebral block for analgesia in patients with traumatic multiple rib fractures.
Read the detailed description
The cases will be randomly selected from Zagazig University emergency Hospital with unilateral multiple rib fractures who admitted to thoracic surgery and emergency departments.
All Cases Will Undergo:
- Patient Examination: All participating patients will be interviewed during their preparation. The goal and end points of the study will be discussed with them. Understanding of the blocks will be reviewed and emphasized and informed written consent regarding the procedure will be taken.
On physical examination, special attention will be given to document vital signs, cardiac, chest condition and exclude contraindications. All patients will be investigated by complete blood count, Liver functions tests, kidney functions tests, coagulation profile, arterial blood gases.
Chest trauma score (CTS) (11) will be applied to all patients The CTS is composed of four different components with a point system assigned:
- age (<45 years = 1, 45-65 = 2, >65 = 3)
- pulmonary contusion (none = 0, unilateral minor = 1, bilateral minor = 2, unilateral major = 3, bilateral major = 4) - number of rib fracture (<3 = 1, 3-5 = 2, >5 = 3) - the presence of bilateral rib fracture = 2.
Number of rib fractures and pulmonary contusion were noted from chest X-ray and Computed Tomography (CT). Each parameter has been assigned specific score and final score was calculated by adding scores of each parameter. Final CTS was then calculated which ranges from 2 to 12.
Chest exercise with incentive spirometry to assess the inhaled tidal volume prior to block.
Patients will be instructed to evaluate pain scores by visual analog scale (VAS), which is a simple assessment tool consisting of a 10 cm line, where 0=no pain at all, 1-2=mild pain intensity,3-5=moderate pain intensity, 6-8=severe pain intensity, and 9-10=worst pain was felt.
Assess respiratory functions by peak expiratory flow meter (PEFR)
- Preparations: Intravenous access will be secured and standard monitoring, Electrocardiogram, pulse oximetry, non-invasive blood pressure, will be attached and baseline parameters, basal ABG, pulmonary functions, VAS score (at rest and during cough). After applying routine monitoring and supplemental oxygen will be given. The patients will be allocated randomly into two equal groups (18 patients in each).
- Group 1 (TPV) (n= 18): After cleaning and draping of thoracic vertebral, paravertebral area and the ultrasound probe, Initial ultrasound scanning of required vertebral and paravertebral region is done. Patient position is either sitting or lateral according to patient's convenience with affected side up. Site of injection is chosen two segments below the most cephalad fractured rib. Linear ultrasound probe of 6-13 MHz probe is used for all sonographic assessments. The appropriate thoracic level is identified by cephalad to caudal ultrasound scanning starting from first rib onwards. Afterwards the spinous process and the transverse process of the appropriate thoracic vertebrae and the rib are identified. The midpoint of the transducer is placed in a longitudinal paramedian plane between two transverse processes of chosen vertebral level. Both transverse processed are visualized with the superior costotransverse ligament (SCTL) and the pleura in between ii) Skin to SCTL distance in mm from lateral border of upper transverse process. iii) Skin to pleura distance in mm from lateral border of upper transverse process. An 18 G needle is introduced using out of plane technique. The tip of the needle is advanced under direct visualization till it pieces the SCTL. 5 ml of bupivacaine 0.25% is injected after negative aspiration, while the spread of local anaesthetic and simultaneously anterior pushing of the pleura is observed Afterwards an additional 10 ml bupivacaine 0.25% with one μg per kg of fentanyl is injected. A catheter is threaded 2-3 cm into the paravertebral space after the block and will be secured with adhesive dressing. The threading of the catheter is graded as easy, some resistance, difficult and not possible. The distance travelled by needle is noted. Then, a perioperative elastomeric infusion of 0.125 percent bupivacaine begins at a rate of 5 ml/h via the paravertebral catheter and maintained for a duration of 48 hours.
- Group 2 (PSIB) (n=18):
While seated with arms draped over body, the patient will receive the PSIB. A high frequency linear ultrasound probe is positioned in a parasagittal plane, at the level of the scapula spine edge, 2 cm from the medial scapular border, while maintaining strict aseptic conditions (fourth rib level). An examination of the trapezius, rhomboid major, iliocostalis, and intercostal muscles is conducted, encompassing both the superficial and deep layers of muscle tissue. By employing an in-plane method, a sono-visible 100 mm 18 G needle is inserted in the vicinity of the fourth rib with a cranial to caudal orientation. The needle is then advanced in the iliocostal-intercostal myofascial plane. Following the confirmation of the needle's position with a 2 ml saline solution, a catheter is inserted 6 cm beyond the needle tip and tunneled beneath the skin. 15 ml of 0.25 percent bupivacaine is injected at the conclusion of the procedure. Then, a perioperative elastomeric infusion of 0.125 percent bupivacaine begins at a rate of 5 ml/h via the PSIB catheter and will be maintained for a duration of 48 hours. Control of breakthrough pain In all groups, if the VAS is at least 3 at rest at any time, a bolus dose of nalbuphine (0.2 mg/kg) will be given for rapid control of pain simultaneously with increasing the infusion rate according to VAS, for severe pain (VAS: 6-8), paracetamol 1gm intravenous infusion every 8 hours is added. catheter removal The catheter will be removed after weaning of infusion rate with accepted VAS, and no more needed.
Data Collection
- Patients characteristic: age, sex, body, height, ASA physical status class, injury severity score (ISS), number of fractured ribs, number of patients with chest tube, length of ICU, and hospital stay.
- bedside monitoring: heart rate, mean arterial pressure, respiratory rate (RR), recorded every hour for the next 48 hours.
- inspiratory exercise tolerance by using Hand-held volume targeted incentive spirometry: Patients will be asked to take five deep breaths through incentive spirometers immediately before analgesia (T0) and post block at 1h (T1), 12h (T2), 24 h (T3), 48h (T4), then each breath will take one point and then points and inhaled volumes will be documented in a table (No. of breaths, tidal volume (600,900,1200, ml as marked on the spirometer)).
- peak expiratory flow rate using peak flowmeter immediately before analgesia (T0) and post block at 1h (T1), 12h (T2), 24 h (T3), 48h (T4) and values will be documented.
- Visual analogue scale (VAS): VAS score will be recorded just before analgesia (T0) and post block at 1h (T1), 12h (T2), 24h (T3), 48h (T4) .at rest and on coughing.
- OTHERS:
A- Arterial blood gases measurements of SpO2, PaCO2, and O2index (i.e. PaO2/FiO2 ratio) and also respiratory rate will be recorded just before analgesia and after analgesia at 1h, 12h, 24 h, and 48 h.
B- Onset time of sensory block:
Time between injection of local anesthetics drugs and loss of pin prick sensation in nerves distributions, pin prick test will be done with sterile 25G needle.
C- amount of total opioid consumption in 48 hours in block groups starting from the beginning of the local anesthetic block.
D- signs related to the thoracic paravertebral complications such as pneumothorax, hemothorax, epidural block, and catheter related infection will be recorded if occurred, vascular and nerve injury will be assessed and recorded.
E- Degree of patient satisfaction on discharge will be assessed and recorded as follows:
- 1.Completely satisfied
- 2.Satisfied
- 3.Neither satisfied nor unsatisfied
- 4.Completely unsatisfied
- Conditions
- Discitis of Thoracic Region
- Being tested
- Thoracic paravertebral block, Parascapular Sub-Iliocostalis Plane Block
- Keywords
- Paravertebral block
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Thoracic paravertebral blockProcedure or surgery
Site of injection is two segments below the most cephalad fractured rib. The midpoint of the transducer is placed in a longitudinal paramedian plane between two transverse processes of chosen vertebral level. An 18 G needle is introduced using out of plane . The tip of the needle is advanced under vision till it pierces the superior costotransverse ligament. 5 ml of bupivacaine 0.25% is injected after negative aspiration, while the spread of local anaesthetic and simultaneously anterior pushing of the pleura is observed Afterwards an additional 10 ml bupivacaine 0.25% with one μg per kg of fentanyl is injected. A catheter is threaded 2-3 cm into the paravertebral space after the block. The distance travelled by needle is noted. A perioperative elastomeric infusion of 0.125 percent bupivacaine begins at a rate of 5 ml/h via the paravertebral catheter and maintained for a duration of 48 hours.
Parascapular Sub-Iliocostalis Plane BlockProcedure or surgery
While seated with arms draped over body, the patient will receive the PSIB. A linear ultrasound probe is positioned in a parasagittal plane, at the level of the scapular spine edge, 2 cm from the medial scapular border (fourth rib level). An examination of the trapezius, rhomboid major, iliocostalis, and intercostal muscles is conducted, encompassing both the superficial and deep layers of muscle tissue. By employing an in-plane method, a sono-visible 100 mm 18 G needle is inserted in the vicinity of the fourth rib with a cranial to caudal orientation. The needle is then advanced in the iliocostal-intercostal myofascial plane. Following the confirmation of the needle's position, a catheter is inserted 6 cm beyond the needle tip and tunneled beneath the skin. 15 ml of 0.25 percent bupivacaine is injected. Then, a perioperative elastomeric infusion of 0.125 percent bupivacaine begins at a rate of 5 ml/h via the PSIB catheter and will be maintained for a duration of 48 hours.
| Study group | Role | What they receive |
|---|---|---|
| Group 1 (TPV) | Active comparator | patients will receive ultrasound guided continuous thoracic paravertebral nerve block Receives: Procedure: Thoracic paravertebral block |
| Group 2 (PSIB) | Active comparator | patients will receive ultrasound-guided continuous parascapular subiliocostalis plane block Receives: Procedure: Parascapular Sub-Iliocostalis Plane Block |
What is being measured
The primary outcome is the main question the study is designed to answer.
pain intensity using VAS.
Patients will be instructed to evaluate pain scores by visual analog scale (VAS), which is a simple assessment tool consisting of a 10-cmline, where 0=no pain at all, 1-2=mild pain intensity,3-5=moderate pain intensity, 6-8=severe pain intensity, and 9-10=worst pain was felt.
Measured: VAS score will be recorded just before analgesia, post block at hour1, hour12 , hour24 and hour48 at rest and on coughing.
Secondary outcomes (4)
inspiratory exercise tolerance by using Hand-held volume targeted incentive spirometry
Patients will be asked to take five deep breaths through incentive spirometers then each breath will take one point and then points and inhaled volumes will be documented in a table (No. of breaths, tidal volume (600,900,1200, ml as marked on the spirometer)
Measured: immediately before analgesia, post block at hour1, hour12, hour24 and hour48
peak expiratory flow rate
Assess respiratory functions by peak expiratory flow meter (PEFR)
Measured: immediately before analgesia, post block at hour1, hour12, hour24 and hour48
Patient satisfaction
Degree of patient satisfaction will be assessed and recorded as follows:
- 1.Completely satisfied
- 2.Satisfied
- 3.Neither satisfied nor unsatisfied
- 4.Completely unsatisfied
Measured: at hour 48
amount of total opioid consumption
total amount of opioid consumption in 48 hours in block groups starting from the beginning of the local anesthetic block will be recorded
Measured: in 48 hours in block groups starting from the beginning of the local anesthetic block.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Mar 2026
- Study start1 May 2025
- Primary completionJan 2027 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Discitis of Thoracic RegionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zagazig University
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- A A El Malky, MD, Study director, Zagazig University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07493473
- Sponsor's protocol ID
- ZU-IRB #1139
- Status last verified
- Mar 2026
- First submitted
- 10 Mar 2026
- Last updated
- 3 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Continuous Block of Parascapular Sub-Iliocostalis Plane Versus Thoracic Paravertebral Plane for Analgesia in Patients With Traumatic Multiple Rib Fractures
- ClinicalTrials.gov ID
- NCT07493473
- Acronym / sponsor ID
- ZU-IRB #1139
- Conditions
- Discitis of Thoracic Region
- Keywords
- Paravertebral block
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- Zagazig UniversityOther government
- Study start
- 1 May 2025 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 25 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pain control of rib fractures is essential for not only primary pain relief but also preventing secondary complications such as atelectasis or pneumonia which increase the hospital stay, as well as the transition to chronic pain.
The cornerstones of analgesic management are oral and intravenous medications such as paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids as well as regional block techniques as paravertebral block and thoracic epidural.
To avoid opioid as well as regional block related side effects such as pneumothorax and hemodynamic instability, previous studies showed that superficial chest wall block such as thoracic erector spinae plane block and serratus anterior plane block had shown a promising success in management of such pain with few side effects.
In an effort to reduce the pain score, hospital stay and improve the patient's capability of physiotherapy this study compares continuous block of parascapular sub-iliocostalis plane block versus continuous thoracic paravertebral block for analgesia in patients with traumatic multiple rib fractures.
Detailed description
The cases will be randomly selected from Zagazig University emergency Hospital with unilateral multiple rib fractures who admitted to thoracic surgery and emergency departments.
All Cases Will Undergo:
- Patient Examination: All participating patients will be interviewed during their preparation. The goal and end points of the study will be discussed with them. Understanding of the blocks will be reviewed and emphasized and informed written consent regarding the procedure will be taken.
On physical examination, special attention will be given to document vital signs, cardiac, chest condition and exclude contraindications. All patients will be investigated by complete blood count, Liver functions tests, kidney functions tests, coagulation profile, arterial blood gases.
Chest trauma score (CTS) (11) will be applied to all patients The CTS is composed of four different components with a point system assigned:
- age (<45 years = 1, 45-65 = 2, >65 = 3)
- pulmonary contusion (none = 0, unilateral minor = 1, bilateral minor = 2, unilateral major = 3, bilateral major = 4) - number of rib fracture (<3 = 1, 3-5 = 2, >5 = 3) - the presence of bilateral rib fracture = 2.
Number of rib fractures and pulmonary contusion were noted from chest X-ray and Computed Tomography (CT). Each parameter has been assigned specific score and final score was calculated by adding scores of each parameter. Final CTS was then calculated which ranges from 2 to 12.
Chest exercise with incentive spirometry to assess the inhaled tidal volume prior to block.
Patients will be instructed to evaluate pain scores by visual analog scale (VAS), which is a simple assessment tool consisting of a 10 cm line, where 0=no pain at all, 1-2=mild pain intensity,3-5=moderate pain intensity, 6-8=severe pain intensity, and 9-10=worst pain was felt.
Assess respiratory functions by peak expiratory flow meter (PEFR)
- Preparations: Intravenous access will be secured and standard monitoring, Electrocardiogram, pulse oximetry, non-invasive blood pressure, will be attached and baseline parameters, basal ABG, pulmonary functions, VAS score (at rest and during cough). After applying routine monitoring and supplemental oxygen will be given. The patients will be allocated randomly into two equal groups (18 patients in each).
- Group 1 (TPV) (n= 18): After cleaning and draping of thoracic vertebral, paravertebral area and the ultrasound probe, Initial ultrasound scanning of required vertebral and paravertebral region is done. Patient position is either sitting or lateral according to patient's convenience with affected side up. Site of injection is chosen two segments below the most cephalad fractured rib. Linear ultrasound probe of 6-13 MHz probe is used for all sonographic assessments. The appropriate thoracic level is identified by cephalad to caudal ultrasound scanning starting from first rib onwards. Afterwards the spinous process and the transverse process of the appropriate thoracic vertebrae and the rib are identified. The midpoint of the transducer is placed in a longitudinal paramedian plane between two transverse processes of chosen vertebral level. Both transverse processed are visualized with the superior costotransverse ligament (SCTL) and the pleura in between ii) Skin to SCTL distance in mm from lateral border of upper transverse process. iii) Skin to pleura distance in mm from lateral border of upper transverse process. An 18 G needle is introduced using out of plane technique. The tip of the needle is advanced under direct visualization till it pieces the SCTL. 5 ml of bupivacaine 0.25% is injected after negative aspiration, while the spread of local anaesthetic and simultaneously anterior pushing of the pleura is observed Afterwards an additional 10 ml bupivacaine 0.25% with one μg per kg of fentanyl is injected. A catheter is threaded 2-3 cm into the paravertebral space after the block and will be secured with adhesive dressing. The threading of the catheter is graded as easy, some resistance, difficult and not possible. The distance travelled by needle is noted. Then, a perioperative elastomeric infusion of 0.125 percent bupivacaine begins at a rate of 5 ml/h via the paravertebral catheter and maintained for a duration of 48 hours.
- Group 2 (PSIB) (n=18):
While seated with arms draped over body, the patient will receive the PSIB. A high frequency linear ultrasound probe is positioned in a parasagittal plane, at the level of the scapula spine edge, 2 cm from the medial scapular border, while maintaining strict aseptic conditions (fourth rib level). An examination of the trapezius, rhomboid major, iliocostalis, and intercostal muscles is conducted, encompassing both the superficial and deep layers of muscle tissue. By employing an in-plane method, a sono-visible 100 mm 18 G needle is inserted in the vicinity of the fourth rib with a cranial to caudal orientation. The needle is then advanced in the iliocostal-intercostal myofascial plane. Following the confirmation of the needle's position with a 2 ml saline solution, a catheter is inserted 6 cm beyond the needle tip and tunneled beneath the skin. 15 ml of 0.25 percent bupivacaine is injected at the conclusion of the procedure. Then, a perioperative elastomeric infusion of 0.125 percent bupivacaine begins at a rate of 5 ml/h via the PSIB catheter and will be maintained for a duration of 48 hours. Control of breakthrough pain In all groups, if the VAS is at least 3 at rest at any time, a bolus dose of nalbuphine (0.2 mg/kg) will be given for rapid control of pain simultaneously with increasing the infusion rate according to VAS, for severe pain (VAS: 6-8), paracetamol 1gm intravenous infusion every 8 hours is added. catheter removal The catheter will be removed after weaning of infusion rate with accepted VAS, and no more needed.
Data Collection
- Patients characteristic: age, sex, body, height, ASA physical status class, injury severity score (ISS), number of fractured ribs, number of patients with chest tube, length of ICU, and hospital stay.
- bedside monitoring: heart rate, mean arterial pressure, respiratory rate (RR), recorded every hour for the next 48 hours.
- inspiratory exercise tolerance by using Hand-held volume targeted incentive spirometry: Patients will be asked to take five deep breaths through incentive spirometers immediately before analgesia (T0) and post block at 1h (T1), 12h (T2), 24 h (T3), 48h (T4), then each breath will take one point and then points and inhaled volumes will be documented in a table (No. of breaths, tidal volume (600,900,1200, ml as marked on the spirometer)).
- peak expiratory flow rate using peak flowmeter immediately before analgesia (T0) and post block at 1h (T1), 12h (T2), 24 h (T3), 48h (T4) and values will be documented.
- Visual analogue scale (VAS): VAS score will be recorded just before analgesia (T0) and post block at 1h (T1), 12h (T2), 24h (T3), 48h (T4) .at rest and on coughing.
- OTHERS:
A- Arterial blood gases measurements of SpO2, PaCO2, and O2index (i.e. PaO2/FiO2 ratio) and also respiratory rate will be recorded just before analgesia and after analgesia at 1h, 12h, 24 h, and 48 h.
B- Onset time of sensory block:
Time between injection of local anesthetics drugs and loss of pin prick sensation in nerves distributions, pin prick test will be done with sterile 25G needle.
C- amount of total opioid consumption in 48 hours in block groups starting from the beginning of the local anesthetic block.
D- signs related to the thoracic paravertebral complications such as pneumothorax, hemothorax, epidural block, and catheter related infection will be recorded if occurred, vascular and nerve injury will be assessed and recorded.
E- Degree of patient satisfaction on discharge will be assessed and recorded as follows:
- 1.Completely satisfied
- 2.Satisfied
- 3.Neither satisfied nor unsatisfied
- 4.Completely unsatisfied
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1 (TPV) | Active comparator | Procedure: Thoracic paravertebral blockpatients will receive ultrasound guided continuous thoracic paravertebral nerve block |
| Group 2 (PSIB) | Active comparator | Procedure: Parascapular Sub-Iliocostalis Plane Blockpatients will receive ultrasound-guided continuous parascapular subiliocostalis plane block |
Who may qualify
- Ages
- 21 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Patient written informed consent.
- ASA I to III.
- Age 21-60 years old.
- Gender: Both.
- BMI < 35 Kg/M2.
Key exclusion criteria (9 listed)
- Any trauma in the patient that interfere with the positioning of patients for block.
- Patients who needed mechanical ventilation before or during the study.
- Patients with associated head trauma.
- Patient with hemodynamic instability and need inotropic support. • Patient with abbreviated injury scale (AIS) in extremity more than 2 (10)
- Pathological coagulopathy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Thoracic paravertebral blockSite of injection is two segments below the most cephalad fractured rib. The midpoint of the transducer is placed in a longitudinal paramedian plane between two transverse processes of chosen vertebral level. An 18 G needle is introduced using out of plane . The tip of the needle is advanced under vision till it pierces the superior costotransverse ligament. 5 ml of bupivacaine 0.25% is injected after negative aspiration, while the spread of local anaesthetic and simultaneously anterior pushing of the pleura is observed Afterwards an additional 10 ml bupivacaine 0.25% with one μg per kg of fentanyl is injected. A catheter is threaded 2-3 cm into the paravertebral space after the block. The distance travelled by needle is noted. A perioperative elastomeric infusion of 0.125 percent bupivacaine begins at a rate of 5 ml/h via the paravertebral catheter and maintained for a duration of 48 hours. | Procedure or surgery | Group 1 (TPV) |
| Parascapular Sub-Iliocostalis Plane BlockWhile seated with arms draped over body, the patient will receive the PSIB. A linear ultrasound probe is positioned in a parasagittal plane, at the level of the scapular spine edge, 2 cm from the medial scapular border (fourth rib level). An examination of the trapezius, rhomboid major, iliocostalis, and intercostal muscles is conducted, encompassing both the superficial and deep layers of muscle tissue. By employing an in-plane method, a sono-visible 100 mm 18 G needle is inserted in the vicinity of the fourth rib with a cranial to caudal orientation. The needle is then advanced in the iliocostal-intercostal myofascial plane. Following the confirmation of the needle's position, a catheter is inserted 6 cm beyond the needle tip and tunneled beneath the skin. 15 ml of 0.25 percent bupivacaine is injected. Then, a perioperative elastomeric infusion of 0.125 percent bupivacaine begins at a rate of 5 ml/h via the PSIB catheter and will be maintained for a duration of 48 hours. | Procedure or surgery | Group 2 (PSIB) |
Primary outcome
pain intensity using VAS.
Time frame: VAS score will be recorded just before analgesia, post block at hour1, hour12 , hour24 and hour48 at rest and on coughing.
Patients will be instructed to evaluate pain scores by visual analog scale (VAS), which is a simple assessment tool consisting of a 10-cmline, where 0=no pain at all, 1-2=mild pain intensity,3-5=moderate pain intensity, 6-8=severe pain intensity, and 9-10=worst pain was felt.
4 secondary outcomes
inspiratory exercise tolerance by using Hand-held volume targeted incentive spirometry
Time frame: immediately before analgesia, post block at hour1, hour12, hour24 and hour48
peak expiratory flow rate
Time frame: immediately before analgesia, post block at hour1, hour12, hour24 and hour48
Patient satisfaction
Time frame: at hour 48
amount of total opioid consumption
Time frame: in 48 hours in block groups starting from the beginning of the local anesthetic block.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
D A Abo El Naga, MSC contact
A A El Malky, MD study director
Zagazig University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Thoracic paravertebral block and Parascapular Sub-Iliocostalis Plane Block in people with Discitis of Thoracic Region, run by Zagazig University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact R A Kamel, MD (+201229927122, ranion8598@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
pain intensity using VAS. (time frame: VAS score will be recorded just before analgesia, post block at hour1, hour12 , hour24 and hour48 at rest and on coughing.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.